LGVN
Longeveron·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 5
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
Price Hits New Low
Price Hits 52-week Low
EPS Below Expectations
Consecutive Revenue Decline
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About LGVN
Longeveron Inc
A clinical stage biotechnology company that develops cellular therapies for specific aging-related and life-threatening conditions
Biological Technology
10/09/2014
02/12/2021
NASDAQ Stock Exchange
25
12-31
Common stock
1951 NW 7th Avenue, Suite 520, Miami, Florida 33136
--
Longeveron Inc was incorporated as a Delaware limited liability company on October 9, 2014 and was authorized to operate in Florida on December 15, 2014. The company is a clinical-stage biotechnology company that develops regenerative medicines to meet unmet medical needs. The company's main research product is Lomecel-B brand MSCs, an allogeneic drug signaling cell (MSC) therapeutic product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has a variety of modes of action, including pro-vascular, pro-regeneration and anti-inflammatory mechanisms, promoting tissue repair and healing, and has a wide range of potential applications in a range of disease fields. The company is currently developing three clinical indications: Left Heart Hypoplasia Syndrome (HLHS), aging-related weakness and Alzheimer's disease (AD).
Earnings Call
Q1/2025
Estimate EPS--
Actual EPS-0.34
Estimate Revenue594.50K
Actual Revenue381.00K
Longeveron's Q1 2025 Earnings Call: Unraveling Contradictions in Manufacturing, Trials, and Market Strategies
May 19,2025 08:57
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS--
Actual EPS-0.33
Estimate Revenue417.75K
Actual Revenue316.00K
Longeveron's Q2 2025 Earnings: Unpacking Key Contradictions in Manufacturing, Regulatory Support, and Clinical Benchmarks
Aug 13,2025 11:04
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
LGVN has released its 2025 Q3 earnings. EPS was reported at -0.39, versus the expected -0.26, missing expectations. The chart below visualizes how LGVN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
LGVN has released its 2025 Q3 earnings report, with revenue of 137.00K, reflecting a YoY change of -82.28%, and net profit of -7.22M, showing a YoY change of -63.41%. The Sankey diagram below clearly presents LGVN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
